CTEV Stock Analysis: Claritev | NYSE
Health Information Services | NYSE, USA | Market Cap: 407m USD | 12M Return: -50.4% | US62548M2098 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.01M
Qual. Beats: 0
Rev. Trend: 60.1%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.6 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Claritev Corporation (NYSE: CTEV), formerly known as MultiPlan Corporation until its February 2025 rebranding, is a U.S.-based healthcare technology company founded in 1980 and headquartered in McLean, Virginia. The company delivers data analytics and technology-enabled solutions focused on cost management, payment processing, and revenue integrity for the healthcare industry. Its offerings span four main areas: claims intelligence (including reference-based pricing, negotiation, and surprise bill services), network solutions (primary and complementary networks along with build and management services), payment and revenue integrity (clinical negotiation and pre- and post-payment integrity services), and data and analytics tools such as PlanOptix, CompleteVue, and BenInsights. Claritev serves a broad customer base including commercial healthcare payers, third-party administrators, employers, brokers and consultants, providers, government healthcare payers, and system integrators, with end clients ranging from national and regional insurers to Blue Cross and Blue Shield plans, provider-sponsored health plans, and property and casualty insurers involved in claims adjudication.
The company operates within the healthcare cost-containment segment, functioning as an intermediary that helps payers and employers manage medical claims expenses and reduce out-of-network billing costs through negotiated rates and analytics-driven insights. As a small-cap stock with a market capitalization of approximately $639 million, Claritev competes alongside other healthcare information services and managed-care technology providers, generating revenue primarily through service fees tied to claims processed and network access rather than through direct patient care or medical device sales.
- UnitedHealth customer concentration drives outsized revenue and margin swings
- No Surprises Act and IDR rulings reshape reference-based pricing economics
- Evolent Health competition pressures share in payment integrity market
| Net Income: -275.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA 1.67 > 1.0 |
| NWC/Revenue: 2.94% < 20% (prev 4.64%; Δ -1.70% < -1%) |
| CFO/TA 0.03 > 3% & CFO 131.3m > Net Income -275.1m |
| Net Debt (4.64b) to EBITDA (507.8m): 9.14 < 3 |
| Current Ratio: 1.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (17.0m) vs 12m ago 3.00% < -2% |
| Gross Margin: 31.29% > 18% (prev 74.72%; Δ -43.43% > 0.5%) |
| Asset Turnover: 21.04% > 50% (prev 19.06%; Δ 1.98% > 0%) |
| Interest Coverage Ratio: 0.15 > 6 (EBIT TTM 59.4m / Interest Expense TTM 398.5m) |
| A: 0.01 (Total Current Assets 224.3m - Total Current Liabilities 194.4m) / Total Assets 4.68b |
| B: -0.56 (Retained Earnings -2.62b / Total Assets 4.68b) |
| C: 0.01 (EBIT TTM 59.4m / Avg Total Assets 4.83b) |
| D: -0.07 (Book Value of Equity -346.6m / Total Liabilities 5.02b) |
| Altman-Z'' = -1.78 = D |
| DSRI: 0.88 (Receivables 133.8m/142.4m, Revenue 1.02b/951.0m) |
| GMI: 2.39 (GM 74.72% / 31.29%) |
| AQI: 0.99 (AQ_t 0.87 / AQ_t-1 0.88) |
| SGI: 1.07 (Revenue 1.02b / 951.0m) |
| TATA: -0.09 (NI -275.1m - CFO 131.3m) / TA 4.68b) |
| Beneish M = -1.84 (Cap -4..+1) = B |
As of November 11, 2026, the stock is trading at USD 28.67 with a total of 932,983 shares traded. Over the past week, the price has changed by +36.52%, over one month by +17.84%, over three months by -15.85% and over the past year by -50.43%.
Current recommended Stop Loss: 26.10 (which is 9% or 1.2 ATR below the current price).
Claritev has received a consensus analysts rating of 4.20. Therefore, it is recommended to buy CTEV.
- StrongBuy: 2
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 46 | 60.4% |
P/E Forward = 3.0979
P/S = 0.4089
P/B = 43.8599
Revenue TTM = 1.02b USD
EBIT TTM = 59.4m USD
EBITDA TTM = 507.8m USD
Long Term Debt = 4.58b USD (from longTermDebt, last fiscal year)
Short Term Debt = 19.3m USD (from shortTermDebt, last quarter)
Debt = 4.65b USD (from shortLongTermDebtTotal, last quarter) + Leases 18.9m
Net Debt = 4.64b USD (calculated: Debt 4.65b - CCE 10.1m)
Enterprise Value = 5.05b USD (406.7m + Debt 4.65b - CCE 10.1m)
Interest Coverage Ratio = 0.15 (Ebit TTM 59.4m / Interest Expense TTM 398.5m)
EV/FCF = -181.6x (Enterprise Value 5.05b / FCF TTM -27.8m)
FCF Yield = -0.55% (FCF TTM -27.8m / Enterprise Value 5.05b)
FCF Margin = -2.73% (FCF TTM -27.8m / Revenue TTM 1.02b)
Net Margin = -27.05% (Net Income TTM -275.1m / Revenue TTM 1.02b)
Gross Margin = 31.29% ((Revenue TTM 1.02b - Cost of Revenue TTM 698.8m) / Revenue TTM)
Gross Margin QoQ = none% (prev 9.09%)
Tobins Q-Ratio = 1.08 (Enterprise Value 5.05b / Total Assets 4.68b)
Interest Expense / Debt = 8.56% (Interest Expense 398.5m / Debt 4.65b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 46.9m (EBIT 59.4m * (1 - 21.00%))
Current Ratio = 1.15 (Total Current Assets 224.3m / Total Current Liabilities 194.4m)
Debt / Equity = -13.43 (negative equity) (Debt 4.65b / totalStockholderEquity, last quarter -346.6m)
Debt / EBITDA = 9.14 (Net Debt 4.64b / EBITDA 507.8m)
Debt / FCF = -166.9 (out of range, set to none) (Net Debt 4.64b / FCF TTM -27.8m)
Total Stockholder Equity = -264.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.69% (Net Income -275.1m / Total Assets 4.68b)
RoE = 104.2% (negative equity) (Net Income TTM -275.1m / Total Stockholder Equity -264.1m)
RoCE = 1.38% (EBIT 59.4m / Capital Employed (Equity -264.1m + L.T.Debt 4.58b))
RoIC = 1.04% (NOPAT 46.9m / Invested Capital 4.49b)
WACC = 7.25% (E(406.7m)/V(5.06b) * Re(12.76%) + D(4.65b)/V(5.06b) * Rd(8.56%) * (1-Tc(0.21)))
Discount Rate = 12.76% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
Shares (quarterly) Correlation: 95.63 | Cagr: 2.33%
[DCF] Fair Price = unknown (Cash Flow -27.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.01 | # QB: 0
Revenue Correlation: 60.13 | Revenue CAGR: 1.85% | SUE: 3.16 | # QB: 2
EPS current Quarter (2027-03-31): EPS=-3.73 | Chg30d=+0.67% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=5.81 | Chg30d=+4.12% | Revisions=+25% | GrowthEPS=+146.2% | GrowthRev=+5.0%
EPS next Year (2027-12-31): EPS=7.33 | Chg30d=+7.16% | Revisions=+25% | GrowthEPS=+26.2% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: +29% (up=3, down=1)